Shots:
- The EC approved Wegovy pill (25mg, QD, PO) as an adjunct to lifestyle intervention for weight management in adults with obesity or overweight, with ≥1 weight-related condition; launch expected in H2’26. The EC also approved Wegovy 7.2mg injection in a single-dose pen for obesity
- Wegovy pill approval was based on the OASIS clinical trial programme (n=~1,300), incl. P-III (OASIS 4) trial assessing oral Wegovy vs PBO over 64wks. in 307 adults with obesity or overweight with ≥1 comorbidities
- OASIS 4 showed oral Wegovy resulted in ~17% weight loss vs 3% with PBO when used alongside lifestyle intervention, plus around one in three pts achieved ≥20% weight loss
Ref: Globenewswire | Image: Novo Nordisk | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
